AbbVie Secures EU Approval for Fast-Acting Aesthetic Toxin Boey

AbbVie (ABBV), through its Allergan Aesthetics unit, has received European Commission approval for Boey (trenibotulinumtoxinE), the first serotype E neurotoxin approved in Europe for treating moderate to severe glabellar lines that have a psychological impact on adults. Boey begins working within 8 hours and lasts about 2-3 weeks, offering a fast and short-lived alternative to other neurotoxins.

The Product

Boey is the first serotype E neurotoxin approved in Europe, with onset as early as 8 hours and a duration of approximately 2-3 weeks. This makes it ideal for patients seeking quick, temporary results for special occasions or first-time users.

Pricing and Availability

Pricing details have not been disclosed yet. Boey is expected to be available in European markets following individual country approvals. It previously received similar approval in Canada.

Competition

Boey competes with products like Botox (onabotulinumtoxinA) from AbbVie itself, Dysport from Ipsen, and Xeomin from Merz. Its rapid onset and short duration may give it a niche advantage for certain patient segments.

Potential Impact on AbbVie

Boey expands AbbVie's aesthetics portfolio, potentially boosting revenue in the cosmetic dermatology segment. However, its short duration may limit repeat usage compared to longer-lasting products.